West R, Hajek P, McNeill A
Psychology Department, Royal Holloway and Bedford New College, London University Egham, Surrey, UK.
Psychopharmacology (Berl). 1991;104(1):91-6. doi: 10.1007/BF02244560.
This paper reports on a double blind trial of the effect of buspirone, 15 mg per day, on cigarette withdrawal symptoms and ability of smokers to maintain abstinence during treatment. A total of 61 smokers were randomly assigned to active or placebo conditions. They were maintained on their drug for 2 weeks prior to attempting abstinence and then for a further 4 weeks of abstinence. Subjects attended weekly group sessions of a psychological treatment programme. There was no evidence that the side effects in the active drug group were worse than those in the placebo group. Although there was no significant difference between active and placebo conditions on withdrawal symptoms, smokers in the active drug condition were more than twice as likely to maintain abstinence for the duration of the study than those in the placebo condition (47% versus 16%, chi square = 5.3, P less than 0.025). The results provide preliminary evidence for short-term efficacy of buspirone as an aid to smoking cessation at a low dose. They also provide evidence of a dissociation between withdrawal symptoms and successful abstinence.
本文报道了一项双盲试验，研究每日15毫克丁螺环酮对戒烟症状以及吸烟者在治疗期间保持戒烟状态能力的影响。共有61名吸烟者被随机分配到活性药物组或安慰剂组。在尝试戒烟前，他们服用各自的药物2周，然后再进行4周的戒烟期。受试者每周参加一次心理治疗项目的小组会议。没有证据表明活性药物组的副作用比安慰剂组更严重。虽然在戒烟症状方面，活性药物组和安慰剂组之间没有显著差异，但在研究期间，活性药物组的吸烟者保持戒烟状态的可能性是安慰剂组的两倍多（47%对16%，卡方=5.3，P<0.025）。研究结果为低剂量丁螺环酮作为戒烟辅助药物的短期疗效提供了初步证据。它们还提供了戒烟症状与成功戒烟之间分离的证据。
